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Abstract: Asvagandha (Withania somnifera) is an important antistress drug has now been sown 
to have an antidepressant action in clinically depressive patients, However, the mechanism of its 
antidepressant action has not been studied. Normal rats fed with asvagandha root extract 
(100mg/kg orally) for 4 and 8 weeks showed enhanced open field behavior and emotional 
stability along with a moderate but significant enhancement in the functional sensitivity of 5 HT2 
receptors in the brain and a reciprocal subsensitivity of the 5HT1A receptors chronic 
asvagandha treatment (propylactically) was effective in preventing the behavioral deficit in open 
field activity in an animal model of depression. This was accompanied by an adaptive 
supersensitivity of the postsynaptic 5HT2 receptors in the brain.  The effect of chronic 
Asvagandha on 5HT receptor subtypes is similar to the action of chronic ECT treatment and 
several antidepressant drugs. 
 
INTRODUCTION  
 
Withania somnifera (Asvagandha) is one of t 
most valuable medicinal herbs1. Apart from 
its vast range of physiological effects
2 recent 
studies have strongly emphasized its 
beneficial effects as an adaptogenic, 
3,6 anti-
stress 
3,6 and tonic agent.  Asvagandha has 
been shown to reduce the incidence of 
aspirin and physical stress induced gastric 
ulcer. 
5 more recently, the total root extracts 
of asvagandha have shown to exhibit 
antistress activity in widely different stress 
situation
3 similarly, it exhibited 
adaptogenic6 and immunostimulatory 
activity, suggesting a high potential of this 
plant as stress lowering agent
6.  
 
Chronic asvagandha has been found to exert 
an anxiolytic action, both in clinical 
7,8,9 as 
well as animal studies
3. 
 
Neurochemical studies have shown that 
chronic Asvagandha induces a depletion of 
acetylcholine and dopamine in the brain and 
increases whole brain level of histamine and 
serotonin.
10 Further, recent clinical trials 
have indicated a considerable therapeutic 
effect of Asvagandha in management of 
clinical depression. Biochemically major 
depression is characterized by a 
dysregulation of central biogenic amine 
neurotransmitter system (mainly 
serotonergic, noradrenergic and 
dopaminergic)
11 The serotonin (5HT) 
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hypothesis of depression has received 
special attention as 5T has been related to 
many of the major symptoms of depression 
eg, sleep, mood, activity and cognitive 
dysfunction.
12,13 Moreover the preclinical 
studies on the action of different types of 
antidepressant treatment on the serotonin 
system revealed, as a common effect, an 
enhancement of the 5HT 
neurotransmission.
13,14 Tricyclic 
antidepressants and electroconvulsive 
therapy enhance the sensitivity of the 
postsynaptic 5HT2 receptors to 5HT.   
%HT1A receptor agonists (effective 
antidepressant) produce the tonic activation 
of postsynaptic 5HT1A receptors. 
14,15 
Monoamine oxidase inhibitors enhance the 
availability of the releasable 5HT uptake 
blockers increase the efficacy of 5HT 
neurons by desensitizing the 5HT 
autoreceptors located on 5HT nerve 
terminals. 
14,15. 
 
Based on the above information, the present 
stud was designed to investigate the effect of 
longterm Asvaganda as a propyllactic 
antidepressant drug, on an well established 
animal model of depression
16.  And 
secondly, to assess the functional sensitivity 
of the 5HT1A and 5HT2 receptors following 
long term Asvaganda administration  
  
 Materials and Methods 
 
Animal:- Adult male albino rats weighing 
150-200 gm. Initially were maintained on an 
adlib rat pellet diet and tap water (unless 
mentioned otherwise) and 12 hr light: dark 
schedule.  The were group housed (3-4 per 
cage) at a room temperature of 24 ± 25
oC. 
 
Drug:- 500g Asvagandha plant root (dried 
and powdered) were extracted with alcohol 
to obtain a 50g extract. A 40% suspension 
was made in distilled water (pyrogen free) 
with the addition of 2% gum acacia powder. 
 
8-OH Di (n-propyl amino tetraline), 5HT 
receptor agonist and 5-MeoDMT 
(5HT1/5HT2 agonist) was dissolved in 0.9% 
saline and freshly made before use. 
 
Depression Model:- A slightly modified 
version of a stress based model developed 
by Kat et al (1982)15 was used.  The 
animals were subjected to a variety of 
different stressors over a 3-week period (6 
day/week). Stressors were administered 
once per day, between the firs and eight our 
of the light cycle to maximize the 
unpredictability on the nature of the 
stressors and time of delivery. A schedule of 
stressors is given in Tale 1. 
 
  Open field Test (OFT):- The apparatus 
consisted of a circular wooden arena (70cm 
in diameter, 30cm height) with a sunmica 
base with three concentric circles divided 
into 24 segments by radial lines originating 
from the centre, Each animal was tested 
individually for 3 min to observe their 
ambulation (number of squares crossed on 
the sunmica base), rearing activity (number 
of times animal stood on its hind limb with 
or without the support of the circular wall) 
and emotional fecal pellet exvretion
17. 
 
Assessment of 5HT Receptor Sensitivity:-  
 
(1a) 5HT1A Receptor:- 5HT1A 
postsynaptic receptor sensitivity was 
assessed by scoring the ‘5HT syndrome’
18 
and ‘hypothermia’
18 elicited by the specific 
5 HTIA agonist 8-OH-DPAT.  The 
syndrome was measured 48h after the last 
treatment (drug or stress) according to the 
method of Backus et al (1990)
19 For testing 
the 15ht syndrome’, rats were placed in an 
observation arena for habituation , 
5,6 min 
before agonist administration. Drug was 
injected 2 min before the first observation 
period and following components of the 
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sybdrome were scored; flat posture, fore 
paw treading, tremor, straub and tail scoring 
was done on a 4-point ranked intensity scale 
as follows:- 
 
0=absent 
1=equivocal 
2=present 
3=extreme 
 
In case of 8-OHDPAt, scording was done in 
observation period of 45 sec per rat, after 
every 5 minutes, for 45 min. scores for each 
component ere summed up over all the 
observation periods scoring was done 
blindly with respect to the treatment given 
minimum four components out of five had 
to be present, in order to accept th5HT 
syndrome as present. 
 
(2b) Hypothermia:- The rectal temperature 
of t eras were measured before the agonist 
injection by a thermister probe (yellow 
spring Co, U.S.A) inserted 5cm into the 
rectum.  Te probe was connected to a 6-
channel telethermometer apparatus 
(APLAB, India).  The rectal temperature 
was again recorded 30 min after 8-OH-
DPAT (0.75 mg/kg, JP) administration. 
18 
 
(3) 5HT2 Postsynaptic Receptor;- 
Postsynaptic 5HT2 receptor function was 
assessed by the induction of wet dog sake 
response (WDS) by 5ht agonist 5 MeO-
DMT (5mg/kg, IP) and quipazine (1mg/kg, 
IP)20 Rats were placed singly in an 
observation cage 5-6 minutes before the 
agonist administration.  The number of 
WDS were counted (by direct observation) 
for 60 min and 40 min for 5MeO – DMT 
and quipazine respectively after agonist 
administration. ‘Wet dog shake is 
characterized as rapid side-to side twitches 
of the lead and ear.
21 
 
Plan of stud:-  
 
After bringing the animals form the central 
animal house, they were housed at the 
laboratory for at least one week before being 
used in experiments,  before starting the 
experiment, all the rats were individually 
tested in the open field (OFT) and high plus 
maze test for assessing their initial 
emotional reactivity and exploratory 
behavior. Reactivity and exploratory 
behavior.  Subsequently, the animals were 
assigned to one of the following groups: 
 
(1) Normal control without drug (n=1) 
(2) 4&8 week Asvagandha treated group 
(n=5) 
(3) Depression group (n=5) 
(4) Depression + Asvagandha (n=5) 
 
In the drug treated control group 
Asvagandha extract (100mg/kg) were fed to 
the rats orally with a feeding tube for either 
4 weeks (6 day/week) or for 8 weeks (6 
day/week).  In the depression group rats 
were subjected to the stress schedule for 8 
weeks.  In the depression + Asvagandha 
group, animal were administered with 
Asvagandha for 1 week and from the second 
week animals were subjected to the stress 
model along with chronic concurrent 
Asvagandha administration for 8 weeks.  All 
the groups were tested in the open field after 
4 weeks and 8 weeks. 5T receptor sensitivity 
were also assessed at the end of four week 
and 8 week. 
 
Statistical Analysis:- The open field activity 
was analyzed by 2-wy ANOVA followed y 
students unpaired or paid t-test for inter or 
intragroup comparison respectively. 
Observer scores for behavioral syndrome 
were analyzed by Mann-whittney U-test.   
The wet dog shake response were analyzed 
by one –way ANOVA, followed by students 
unpaired t-test. 
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Results:- 
 
In normal tats 4 week Asvagandha 
administration did not significantly change 
the behaviour of the animals in the OFT.   
However, 8 week treatment significantly 
increased the ambulation and rearing 
activity (p<0.05) (Table 2). 
 
Table 3 shows that in the depression model, 
after 4 week stress, the rats sowed 
significant psychomotor retardation and 
inactivity as shown by a significant 
reduction in ambulation. 
 
(p<0.01) as well as rearing (p<0.01), wile 
pellet excretion was increased (t= 2.9 
p<0.05) when compared to prestress level. 
After 8 week of stress, the rats showed 
further reduction in ambulation (t= 4.8, p< 
0.001), rearing (t = 4.42, p< 0.001) and 
increase in pellet excretion as compared to 
prestress level.  Moreover, the animals 
showed extreme hesitation towards 
exploration of the center of the open field 
and remained mostly huddled near the wall 
of the arena.  Grooming activity was also 
not observed. 
 
When Asvagandha was administered 
concurrently with stressors 
(prophylactically) after 4 week, there was a 
significant improvement of the deficits. 
However, still ambulation was 16% less 
than prestress level.  At the end of 8 weeks 
Asvagandha treatment, the stress + drug 
group exhibited 180% higher ambulatory 
actually (p<0.001) and 500% higher rearing 
activity (p<0.001) as compared to the 
depression group (Table 3). 
 
5HT1A Receptor Mediated Behavioural 
Syndrome:- 
 
Table 4 shows that following 4 week 
Asvagandha treatment to normal rats, two 
components of the ‘5Ht syndrome’ viz fore 
paw padding and flat posture showed a 
significantly diminished response (P<0.05, 
P<0.05 resp.). Further, the hypothermic 
effect of 5HT1A receptor agonist was 
significantly potentiated in normal drug 
treated animal as compared to control.   
Following 8 week Asvagandha 
administration to normal rats, out of five 
components of 5T syndrome, tremor and flat 
posture showed a significantly diminished 
response (p,0.01, P<0.01 resp) The degree 
of hypothermia induced by 8- OH-DPAt 
remained similar to that after 4 – week drug 
treatment . 
 
Table 5 shows that in the behaviorally 
depressed group (8 – week stress) tremor 
and flat posture were slightly enhanced 
(P<0.05, P<0.01) while other components 
remained unaltered compared to the control 
group. Table 5 also shows that when 
Asvagandha was administered 
prophyllactically for 8 weeks, tremor and 
flat posture were decreased significantly (P< 
0.05 both group respectively) compared to 
depression group. The effect of Asvagandha 
was essentially similar to its effect on 
normal rats. 
 
5HT2 Receptor Mediated Syndrome:- 
 
Table 6 shows that in normal 4 week drug 
fed rats the WDS response week drug fed 
rats the WDS response showed a tendency 
to increase.  However, the following 8 
weeks of Asvagandha feeding, 5MeO-DMT 
induced WDS was significantly enhanced 
(P<0.05).  In the behaviourally depressed 
rats where as apparently no alteration in the 
WDS response both 5MeO-DMT 2 
quipazine.  When Asvagandha s 
administered orally (prophylactically) 
concurrent with stressors, there was a 
significant enhancement (P<0.01) in the 
WDS after 8 weeks which was also 
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confirmed with quipazine (5HR1/5HT12 
agonist). 
 
Discussion 
 
Our data shows that normal rats treated with 
Asvagandha extract (for 8 weeks) exhibited 
less emotional reactivity and slightly 
heightened exploratory activity in the open 
field.  4 weeks Asvagandha treatment 
resulted in a significant diminution in the 
functional sensitivity of the 5HT1A 
postsynaptic receptors, as indicated by the 
reduced expression of ‘5HT syndrome’.  Tis 
syndrome is the most consistently utilized 
model to assess the sensitivity of the   
5HT1A neurons.
22 Behavioral studies also 
suggest that sensitivity of the 5HT1A   
receptors are decreased in brain stem region 
after long term (4-6 weeks) antidepressant 
therapy, 
18,23.  Out data also indicate that the 
sensitivity of the postsynaptic 5HT2 
receptors was moderately enhanced 
following administration of Asvagandha, 
both, after 4 and 8 weeks, as indicated by 
the enhanced WDS syndrome. WDS 
response has been shown to be mediated by 
the postsynaptic 5HT2 receptors 
20, 24 and 
the neural substrat is located rostral to 
bnulbospinal serotonergic nerons.
24 Many of 
the popular antidepressant drugs 
25,26 have 
also shown to enhance the behavioral 
responsiveness (WDS) of 5HT2 receptors 
following chronic administration animal 
models.  Electrophysiological studies have 
shown that the sensitivity to iontophortically 
applied 5HT is significantly enhanced b 
treatment with tricycles and ECS. 
27, 28 
 
Our finding with the animalmodel of 
depression (chronic stress model of Katz et 
al) confirms the previous observations with 
this model. 
16,17 this model was particularly 
chosen mainly for the following reasons; fist 
this is one of models with highest overall 
validity,
29 since the effects observed in the 
model increased corticosterone level, a lack 
of reactivity to an acute stress, 
16 
suppression of open field activity and 
anhedonia 30,31 – are all central features of 
clinical depression. Secondly, it offered the 
opportunity to study the prophylactic effect 
of long term drug treatment. Results show 
that after 4 weeks of stress, the rats 
exhibited significant deficit in psychomotor 
activity and increases emotional defecation. 
However, the diminution of psychomotor 
activity and exploratory activity became 
more pronounced at the end of 8 week.  In 
these animals alterations in 5HT1A receptor 
sensitivity was less clear, as only one 
component sowed enhanced response while 
majority of components remained 
unchanged, the sensitivity of the 5HT2 
receptors was also unaltered in this model 
which confirm the earlier results.
32 Earlier 
studies have shown that 5HT synthesis and 
turnover were significantly decreased in 
several brain areas in this model of 
depression. 
32 thus, an impaired 5HT 
function at the presynaptic level may be one 
of the major factors contributing to the 
behavioural deficit observed. 
 
Finally, the most significant finding in the 
present study was the ability of 8-week 
asvagandha treatment in preventing 
(propylactically) the development of 
behavioural deficit in 100% of the animals 
tested in the OFT.  Similar reversal of the 
open field behavior deficit have also been 
reported following chronic prophylactic 
treatment with imipramine, amitryptylene 
and ECT, 
30,31 Also these animal exhibited a 
significant enhancement in the functional 
sensitivity of the 5HT2  receptors. Such 
adaptive supersensitivity of the 5HT2   
receptors may have an important role in 
mediating the antidepressant effect of 
Asvagandha in this model by increasing the 
serotonergic neurotransmission.  The 
proposition that a serotonergic component 
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dos have a primary role in mediating the 
antidepressant action is strengthened by the 
fact that drugs the primarily effect the 5HT 
system were able to reverse many of the 
behavioural deficit observed in the Katz 
model; dopaminergic, GABA ergic, 
cholinergic agents and benzodiaeperies ere 
found to be ineffective.
23 Moreover, the 
possibility the adaptation of 5HT2 receptors 
following Asvagandha treatment is related 
to the antidepressant action in clinical 
situation is considerably strengthened by the 
fact that following ECS therapy (still 
considered  as the most effective therapy), 
both 5HT2  receptor responsiveness, as well 
as 5HT2  receptor binding in cerebral cortex 
are significantly enhanced in animal models. 
14,25,34 
 
In summary, 8 week Asvagandha-treated 
normal tats exhibited ore emotional stability 
in open field test compared to pre-drug level 
as well as control chronic Asvagandha 
treatment resulted in enhancement of 5HT2 
receptor responsiveness and a reciprocal 
decrease in 5HT1A receptor responsiveness. 
Also, 8 week Asvagandha treatment 
(prophylactically) prevented the behavioural 
deficit in an animal model of depression.   
This was associated with an remarkable 
enhancement in the sensitivity of 5HT2   
receptor responsiveness.  The effect of 
Asvagandha on the 5HT receptor subtypes 
are similar to the action of several 
antidepressant drugs. 
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Table -1 
Schedule of stressors administered (the schedule was repeated after 21 days) 
  
Day  Type of Stressors  Duration 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Restraint stress 
Cold stress, 0oC 
Shake stress 
Individual housing  
Individual housing 
Food deprivation  
Noise stress, 95 db 
Cold water stress 0oC 
Soiled cage 
Reversal of day/night 
Reversal of day/night 
Food deprivation  
Noise stress, 95 db 
Cold water swin 
Restraint stress 
Tail pinch 
Heat stress 380C 
Food deprivation  
Reversal of day/night 
5 min 
15 min 
30 min 
24hr 
24hr 
24hr 
5 min 
5 min 
24hr 
24hr 
24hr 
24hr 
5 min 
5 min 
5 min 
5 min 
15 min 
24hr 
24hr 
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20 
21 
Noise stress, 95 db 
Food deprivation  
5 min 
24hr 
                  
Table -2 
Open field behaviour of rats during 4 week and 8 week Asvagandha administration (100mg/kg 
given orally) 
 
Group Ambulation  Rearing  Pellet 
Control 
(n =10) 
0 week 
4 week 
8 week 
Control ± 
Asvagandha  
(n =10) 
0 week 
4 week 
8 week 
 
 
87.2 ± 6.9 
83.5 ± 5.2 
89.5 ± 2.3 
 
 
 
86.3 ± 7.3 
89.0 ± 7.2 
108.0  ± 8.7*  
 
 
18.5 ± 2.7 
16.2 ± 1.1 
17.1 ± 0.9 
 
 
 
15.6 ± 0.9 
21.2 ± 3.9 
19.4 ± 2.5* 
 
 
2.6 ± 0.6 
2.0 ± 0.8 
2.0 ± 0.9 
 
 
 
2.6 ± 0.6 
0 
0* 
     
Data expressed as Mean ± S.E. N= Number of animal used. 
*P<0.005 compared to 0 week value of control + Asvagandha  
 
Table -3 
Open field behaviour of rats in depression group and depression + Asvagandha group. 
 
Group Ambulation Rearing  Pellet 
Control 
(n =10) 
 
Depression (n=10) 
 
0 week 
4 week 
8 week 
 
Control± Asvagandha  
(n =10) 
 
0 week 
4 week 
8 week 
 
80.5 ± 10.7 
 
 
 
84.2 ± 9.08 
59.1 ± 2.5 ** 
36.0 ± 10.3*** 
 
 
 
 
96.6 ± 7.3 
80.2 ± 6.6 
95.7 ± 15.4 *** 
 
18.4 ± 2.3 
 
 
 
17.0 ± 3.5 
10.1 ± 1.3 ** 
2.5 ± 0.3*** 
 
 
 
 
20.2 ± 2.9 
15.4 ± 2.5 
16.2 ± 3.1*** 
 
0 
 
 
 
1.8 ± 0.8 
4.7 ± 0.6* 
2.4 ± 2.5 
 
 
 
 
0 
1.7 ± 0.73 
1.2 ± 0.09 
     
Data expressed as Mean ± S.E. N= Number of animals.  Data analysed by 1 way ANOVA 
followed by students t- test *** P< 0.001 significantly different from prestress level (0 week). 
*** P< 0.001 compared to 8 week depression group. 
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Table -4 
5HT1A receptor mediated 5HT syndrome elicited by 8-OH-DPAT (0.75 mg/kg, IP) in normal 
control, and after 4 week and 8 week Asvaganda treatment  
 
 Data expressed as Mean ± S.E. N = Number of rats. Data analysed by Mann- Whitney U- test; 
P<0.05; **P<0.01 significantly different form control group. 
 
 Table -5 
5HT syndrome elicited by 8-OH-DPAT (0.75 mg/kg, IP) in normal control, depression and 
depression + Asvagandha group. 
 
 Data expressed as Mean ± S.E. N = Number of rats. *P<0.05; **P<0.01 compared to control. 
*P< 0.05 compared to depression. 
  
Table -6 
5 MeO – DMT and Quipazine elected ‘Wet dog shake’ response (5HT2 receptor mediated) in 
control, 4 and 8 week Asvagandha treated, depression and depression + Asvaganda  
Group 
 
Control 
(n=5) 
Cont + 4 
week 
asva. 
(n=5) 
Cont + 8 
week 
asva. 
(n=5) 
Dep. 
(n=5) 
 
Dep. 
+ 4 week 
asva. 
(n=5) 
Dep. 
+ 8 week 
asva. 
(n=5) 
5MeO – DMT 
(5mg/kg) 
 
Quipazine 
(1mg/kg) 
5.2 ± 0.9 
 
 
15.0 ± 1.5 
7.3 ± 0.5 
 
 
-- 
9.3 ± 0.5* 
 
 
-- 
4.5 ± 1.1 
 
 
13.5 ± 0.6 
7.0 ± 1.1 
 
 
18.8 ± 2.3 
13.1 ± 0.6** 
 
 
26.2 ± 1.5*** 
 
Data expressed as Mean ± S.E. N = Number of rats. *P< 0.05 compared to control **P<0.01; 
***P<0.01 compared to depression group. 
Components of 
5HT Syndrome 
Control  Control + 4 wk 
Asvagandha 
Control + 8 wk 
Asvagandha 
Tremor  9.00 ± 0.6  10.1 ± 0.8  7.8 ± 0.66** 
Flat posture  22.4 ± 2.2  15.3 ± 2.8*  11.0 ± 1.9** 
Forepaw treading  3.3 ± 0.8  1.3 ± 0.9*  3.4 ± 1.5 
Head weaving  12.4 ± 1.2  12.8 ± 1.7  18.2 ± 0.9** 
Straub tail  2.2 ± 1.5  3.3 ± 0.9  2.4 ± 0.74 
Hypothermia  -0.70 ± 0.2  1.8 ± 0.02  -1.2 ± 0.35 
Components of 
5HT Syndrome 
Control  Depression (8 wk stress)    Depression  + 
Asvagandha 
Tremor  9.00 ± 0.6  11.6 ± 0.8*  8.1 ± 0.5* 
Flat posture  22.4 ± 2.2  16.4 ± 2.4**  12.4 ± 1.2* 
Head weaving  12.4 ± 1.2  12.0 ± 0.9  13.2 ± 1.6 
Straub tail  2.2 ± 1.5  3.0 ± 1.4  2.2 ± 0.1 
Hypothermia  -0.70 ± 0.23  -1.96 ± 1.1  -2.3 ± 0.14* 
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